tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
EyePoint Pharmaceuticals: Promising Phase 3 Trial Progress and Strategic Advancements Justify Buy Rating
PremiumRatingsEyePoint Pharmaceuticals: Promising Phase 3 Trial Progress and Strategic Advancements Justify Buy Rating
21d ago
EyePoint price target raised to $23 from $22 at H.C. Wainwright
Premium
The Fly
EyePoint price target raised to $23 from $22 at H.C. Wainwright
21d ago
EyePoint reports Q2 EPS (85c), consensus (80c)
Premium
The Fly
EyePoint reports Q2 EPS (85c), consensus (80c)
21d ago
EyePoint Completes Enrollment for Phase 3 Trials
PremiumCompany AnnouncementsEyePoint Completes Enrollment for Phase 3 Trials
29d ago
EyePoint completes enrollment of Phase 3 trials for DURAVYU in wet AMD
Premium
The Fly
EyePoint completes enrollment of Phase 3 trials for DURAVYU in wet AMD
29d ago
EYPT Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
EYPT Earnings this Week: How Will it Perform?
1M ago
EyePoint Pharmaceuticals: Strategic Advancements and Promising Developments Support Buy Rating
PremiumRatingsEyePoint Pharmaceuticals: Strategic Advancements and Promising Developments Support Buy Rating
3M ago
EyePoint Completes Enrollment for DURAVYU Phase 3 Trial
Premium
Company Announcements
EyePoint Completes Enrollment for DURAVYU Phase 3 Trial
3M ago
EyePoint completes enrollment in Phase 3 LUGANO trial of DURAVYU
Premium
The Fly
EyePoint completes enrollment in Phase 3 LUGANO trial of DURAVYU
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100